Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial

Yoram Kluger, Bruno Riou, Rolf Rossaint, Sandro B Rizoli, Kenneth David Boffard, Philip Iau Tsau Choong, Brian Warren, Michael Tillinger, Yoram Kluger, Bruno Riou, Rolf Rossaint, Sandro B Rizoli, Kenneth David Boffard, Philip Iau Tsau Choong, Brian Warren, Michael Tillinger

Abstract

Background: Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is being investigated as an adjunctive hemostatic treatment for bleeding refractory to conventional replacement therapy in trauma patients. TBI is a common component of polytrauma injuries. However, the combination of TBI with polytrauma injuries is associated with specific risk factors and treatment modalities somewhat different from those of polytrauma without TBI. Although rFVIIa treatment may offer added potential benefit for patients with combined TBI and polytrauma, its safety in this population has not yet been assessed. We conducted a post hoc sub analysis of patients with TBI and severe blunt polytrauma enrolled into a prospective, international, double-blind, randomized, placebo-controlled study.

Methods: A post hoc analysis of study data was performed for 143 patients with severe blunt trauma enrolled in a prospective, randomized, placebo-controlled study, evaluating the safety and efficacy of intravenous rFVIIa (200 + 100 + 100 microg/kg) or placebo, to identify patients with a computed tomography (CT) diagnosis of TBI. The incidences of ventilator-free days, intensive care unit-free days, and thromboembolic, serious, and adverse events within the 30-day study period were assessed in this cohort.

Results: Thirty polytrauma patients (placebo, n = 13; rFVIIa, n = 17) were identified as having TBI on CT. No significant differences in rates of mortality (placebo, n = 6, 46%, 90% confidence interval (CI): 22% to 71%; rFVIIa, n = 5, 29%, 90% CI: 12% to 56%; P = 0.19), in median numbers of intensive care unit-free days (placebo = 0, rFVIIa = 3; P = 0.26) or ventilator-free days (placebo = 0, rFVIIa = 10; P = 0.19), or in rates of thromboembolic adverse events (placebo, 15%, 90% CI: 3% to 51%; rFVIIa, 0%, 90% CI: 0% to 53%; P = 0.18) or serious adverse events (placebo, 92%, 90% CI: 68% to 98%; rFVIIa, 82%, 90% CI: 60% to 92%; P = 0.61) were observed between treatment groups.

Conclusion: The use of a total dose of 400 (200 + 100 + 100) microg/kg rFVIIa in this group of hemodynamically unstable polytrauma patients with TBI was not associated with an increased risk of mortality or with thromboembolic or adverse events.

References

    1. Centers for Disease Control and Prevention (CDC) Rates of hospitalization related to traumatic brain injury – nine states, 2003. MMWR Morb Mortal Wkly Rep. 2007;56:167–170.
    1. Hoyt DB. A clinical review of bleeding dilemmas in trauma. Semin Hematol. 2004;41:40–43. doi: 10.1053/j.seminhematol.2003.11.009.
    1. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995;38:185–193.
    1. Hoyt DB, Bulger EM, Knudson MM, Morris J, Ierardi R, Sugerman HJ, Shackford SR, Landercasper J, Winchell RJ, Jurkovich G, et al. Death in the operating room: an analysis of a multi-center experience. J Trauma. 1994;37:426–432.
    1. Koh MB, Hunt BJ. The management of perioperative bleeding. Blood Rev. 2003;17:179–185. doi: 10.1016/S0268-960X(02)00062-0.
    1. Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev. 2003;17:S11–S21. doi: 10.1016/S0268-960X(03)90002-6.
    1. Lynn M, Jeroukhim I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. 2002;28:S241–S247. doi: 10.1007/s00134-002-1471-7.
    1. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709–718.
    1. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431–438.
    1. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3:640–648. doi: 10.1111/j.1538-7836.2005.01203.x.
    1. Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma. 2005;59:150–154.
    1. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198–208. doi: 10.1097/00000542-200607000-00030.
    1. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Task Force for Advanced Bleeding Care in Trauma et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11:R17. doi: 10.1186/cc5686.
    1. Rizoli S, Nascimento B, Osman F, Netto FS, Kiss A, Callum J, Brenneman FD, Tremblay L, Tien HC. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma. 2006;61:1419–1425.
    1. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective. Crit Care. 2006;10:R120. doi: 10.1186/cc5026.
    1. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y, NovoSeven Trauma Study Group Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–15.
    1. Dereeper E, Ciardelli R, Vincent JL. Fatal outcome after polytrauma: multiple organ failure or cerebral damage? Resuscitation. 1998;36:15–18. doi: 10.1016/S0300-9572(97)00080-4.
    1. Søreide E, Deakin CD. Pre-hospital fluid therapy in the critically injured patient – a clinical update. Injury. 2005;36:1001–1010. doi: 10.1016/j.injury.2005.01.002.
    1. Maas AIR, Dearden M, Teasdale GM, Braakman R, Cohadon F, Iannoti F, Karimi A, Lapierre F, Murray G, Ohman J, et al. EBIC guidelines for management of severe head injury in adults. Acta Neurichir. 1997;139:286–294. doi: 10.1007/BF01808823.
    1. Vincent JL, Berré J. Primer on medical management of severe brain injury. Crit Care Med. 2005;33:1392–1399. doi: 10.1097/01.CCM.0000166890.93559.2D.
    1. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–785. doi: 10.1056/NEJMoa042991.
    1. Hawryluk GW, Cusimano MD. The role of recombinant activated factor VII in neurosurgery: hope or hype? J Neurosurg. 2006;105:859–868.
    1. Zaaroor M, Bar-Lavie Y. The use of recombinant factor VIIa in head injury: a report of five cases. Semin Hematol. 2004;41(1 Suppl 1):175–176. doi: 10.1053/j.seminhematol.2003.11.033.
    1. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulation in pediatric patients. Report of three cases and review of the literature. J Neurosurg. 2003;98:611–616.
    1. Park P, Fewel ME, Garton HJ, Thompson G, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53:34–38. doi: 10.1227/01.NEU.0000068830.54968.A8.
    1. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98:737–740.
    1. Heisel M, Nagib M, Madsen L, Alshiekh M, Bendel A. Use of recombinant factor VIIa (rFVIIa) to control intraoperative bleeding in pediatric brain tumor patients. Pediatr Blood Cancer. 2004;43:703–705. doi: 10.1002/pbc.20144.
    1. Karadimov D, Binev K, Nachkov Y, Platikanov V. Use of activated recombinant factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol. 2003;15:330–332. doi: 10.1097/00008506-200310000-00008.
    1. Gerlach R, Marquardt G, Wissing H, Scharrer I, Raabe A, Seifert V. Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report. J Neurosurg. 2002;96:946–948.
    1. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit. 2002;8:CS98–CS100.
    1. Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia. 2000;6:50–54. doi: 10.1046/j.1365-2516.2000.00345.x.
    1. Siegel LJ, Gerigk L, Tuettenberg J, Dempfle CE, Scharf J, Fiedler F. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology. 2004;100:441–443. doi: 10.1097/00000542-200402000-00037.
    1. Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, Matthews J, Minhas P, Hutchinson PJ, Menon D, et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis. 2000;11:S117–S120.
    1. Pathak A, Dutta S, Marwaha N, Singh D, Varma N, Mathuriya SN. Change in tissue thromboplastin content of brain following trauma. Neurol India. 2005;53:178–182.
    1. Stein SC, Smith DH. Coagulopathy in traumatic brain injury. Neurocrit Care. 2004;1:479–488. doi: 10.1385/NCC:1:4:479.
    1. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879. doi: 10.1016/S0140-6736(99)05155-7.
    1. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006;124:747–757. doi: 10.1016/j.jbiotec.2006.03.042.
    1. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol. 2004;41:65–69. doi: 10.1053/j.seminhematol.2003.11.013.
    1. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884–888.
    1. Martinowitz U, Zaarur M, Yaron BL, Blumenfeld A, Martonovits G. Treating traumatic bleeding in a combat setting: possible role of recombinant activated factor VII. Mil Med. 2004;169:16–18.
    1. Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007;83:707–714. doi: 10.1016/j.athoracsur.2006.10.033.
    1. Segal S, Shemesh IY, Blumental R, Yoffe B, Laufer N, Mankuta D, Mazor M, Zohar S, Schiff E, Martinovitz U. The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand. 2004;83:771–772. doi: 10.1111/j.0001-6349.2004.00501.x.
    1. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth. 2005;94:592–595. doi: 10.1093/bja/aei094.
    1. Welsby IJ, Monroe DM, Lawson JH, Hoffmann M. Recombinant activated factor VII and the anaesthetist. Anaesthesia. 2005;60:1203–1212. doi: 10.1111/j.1365-2044.2005.04376.x.
    1. Midathada MV, Mehta P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol. 2004;121:124–137. doi: 10.1309/D0G0-C96V-05CJ-5B4J.
    1. Arkin S, Cooper HA, Hutter JJ, Miller S, Schmidt ML, Seibel NL, Shapiro A, Warrier I. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis. 1998;28:93–98. doi: 10.1159/000022418.
    1. Roberts HR. Recombinant factor VIIa: how safe is the stuff? Can J Anaesth. 2005;52:8–11.
    1. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899–909. doi: 10.1111/j.1538-7836.2004.00759.x.
    1. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006;46:919–933. doi: 10.1111/j.1537-2995.2006.00824.x.
    1. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883–890. doi: 10.1097/01.CCM.0000159087.85970.38.
    1. Levi M. Recombinant factor VIIa: a general hemostatic agent? Not yet. J Thromb Haemost. 2004;2:1695–1697. doi: 10.1111/j.1538-7836.2004.00912.x.
    1. Roberts HR, Monroe DM, 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41:101–108. doi: 10.1053/j.seminhematol.2003.11.019.
    1. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–298. doi: 10.1001/jama.295.3.293.
    1. Romano JG, Forteza AM, Concha M, Koch S, Heros RC, Morcos JJ, Babikian VL. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;50:1026–1030. doi: 10.1097/00006123-200205000-00016.
    1. Thomas GO, Dutton RP, Hemlock B, Stein DM, Hyder M, Shere-Wolfe R, Hess JR, Scalea TM. Thromboembolic complications associated with Factor VII administration. J Trauma. 2007;62:564–569.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa